Use of In Vitro Vancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide

Oritavancin is a recently approved lipoglycopeptide antimicrobial agent with activity against Gram-positive pathogens. Its extended serum elimination half-life and concentration-dependent killing enable single-dose treatment of acute bacterial skin and skin structure infections. At the time of regul...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Jones, Ronald N., Turnidge, John D., Moeck, Greg, Arhin, Francis F., Mendes, Rodrigo E.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2015
Matèries:
Susceptibility
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4356816/
https://ncbi.nlm.nih.gov/pubmed/25666152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.05098-14
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars